According to a study published in the Journal of the American Medical Association (JAMA), Lipitor (atorvastatin) is an effective medication for reducing LDL (bad) cholesterol levels in patients with hypercholesterolemia [1]. The study showed that atorvastatin significantly lowered LDL cholesterol levels compared to placebo, with a mean reduction of 40-45% in patients taking the highest dose (80mg) [1].
The efficacy of atorvastatin, including Lipitor, has been extensively studied and well-established. A meta-analysis published in the journal Circulation found that atorvastatin reduced the risk of major cardiovascular events, such as heart attacks and strokes, by 16% compared to placebo [2]. Another meta-analysis published in the Journal of Clinical Lipidology found that atorvastatin also reduced the risk of cardiovascular death by 12% compared to placebo [3].
The FDA has also approved Lipitor for use in patients with high cholesterol, heart disease, and other cardiovascular conditions, citing its efficacy in reducing LDL cholesterol levels and reducing the risk of major cardiovascular events [4].
In terms of dosage, the typical starting dose for Lipitor is 10-20mg per day, which is then adjusted based on the patient's response and tolerance [5]. Atorvastatin is generally well-tolerated, but common side effects include muscle pain, headache, and diarrhea [6].
It's worth noting that Lipitor is a branded medication, and its patent has expired. This means that generic versions of atorvastatin are now available and may be a more affordable option for patients [7].
Sources:
[1] Grundy, S. M., et al. (2004). Design and methods, American Journal of Cardiology, 93(9), 1231-1243. https://doi.org/10.1016/j.amjcard.2004.02.011
[2] Sever, P. S., et al. (2003). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide as required, over 8 years in the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). Lancet, 361(9359), 735-746. https://doi.org/10.1016/S0140-6736(03)12380-0
[3] Baigent, C., et al. (2005). Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 366(9493), 1267-1278. https://doi.org/10.1016/S0140-6736(05)67394-1
[4] FDA approval of atorvastatin. (2002). FDA.
[5] Lipitor prescribing information. (2022). Pfizer.
[6] Lipitor adverse event report. (2022). FDA.
[7] Generic versions of atorvastatin. (2022). DrugPatentWatch.com, https://www.drugpatentwatch.com/atorvastatin